( April 1, 2026, 8:58 AM EDT) -- WASHINGTON, D.C. — The manufacturers of Dupixent XE "Dupixent"
, a prescription medication used for the treatment of asthma and inflammatory skin conditions that individuals in cases across the country allege causes cutaneous T-cell lymphoma (CTCL), a rare type of cancer that affects white blood cells called T cells or T lymphocytes, agree with plaintiffs that the cases should be centralized by the U.S. Judicial Panel on Multidistrict Litigation (JPMDL) but argue that New York is a more proper venue....